Variables that were included in the final univariate and multivariate analyses were: age, gender, sites of disease, treatment lines, tumour pathology, PS and laboratory parameters.
Relevant clinical and laboratory values for septic and critically-ill non-septic patients regarding median age, gender, sites of infection, severity of illness scores, mortality, length of ICU stay and so on are provided in Table 1.
The two datasets were quite similar with respect to the distributions of several prognostic factors, including age, Breslow depth, number of nodes, performance status, gender, site of primary, and stage of disease.
Comparisons of telomere length in normal and neoplastic tissues according to gender, site of disease, tumour stage and grade, MSI and p53 status were performed using the Kruskal Wallis test.
There were no differences in life expectancy based on age, gender, site of primary tumor, or number/site of DM.
The results were expressed as percentage of cellular component encountered in the mussel mantle per gender, site and sampling time.
Thus, it would only be detectable if considered in conjunction with known risk factors such as genetics, gender, site of cancer, age, and health behaviors, such as smoking.
Thus, neither age, gender, site-specific EBP, nor post-EBP regimen seems to explain the differences found between this series and earlier published results.
Other clinical variables including gender, site of primary tumor (colon, sigmoid-rectum junction, rectum, other sites), and age were not significantly associated with objective tumor response (p = 0.491, 0.490 and 0.904, respectively; p values were obtained by Fisher's exact test for site and gender and by Wald's test for age).
No significant difference was evident by age, gender, site, or rank.
The prognostic factors analysed for effect were performance status, age, gender, site of primary tumour, treatment arm and tumour differentiation.
